Magellan Health (NASDAQ:MGLN) and Its Peers Financial Survey

Magellan Health (NASDAQ: MGLN) is one of 15 public companies in the “Managed Health Care” industry, but how does it contrast to its competitors? We will compare Magellan Health to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Magellan Health and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Magellan Health 1 0 3 0 2.50
Magellan Health Competitors 81 931 1473 24 2.57

Magellan Health presently has a consensus target price of $81.25, indicating a potential downside of 2.46%. As a group, “Managed Health Care” companies have a potential downside of 1.87%. Given Magellan Health’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Magellan Health has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

93.3% of Magellan Health shares are held by institutional investors. Comparatively, 90.6% of shares of all “Managed Health Care” companies are held by institutional investors. 3.6% of Magellan Health shares are held by insiders. Comparatively, 2.4% of shares of all “Managed Health Care” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Magellan Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Magellan Health $4.84 billion $77.87 million 21.98
Magellan Health Competitors $50.73 billion $1.52 billion 12.06

Magellan Health’s competitors have higher revenue and earnings than Magellan Health. Magellan Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Magellan Health has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Magellan Health’s competitors have a beta of 0.62, indicating that their average share price is 38% less volatile than the S&P 500.


This table compares Magellan Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Magellan Health 1.68% 9.20% 4.21%
Magellan Health Competitors 1.81% 11.16% 3.57%


Magellan Health competitors beat Magellan Health on 8 of the 13 factors compared.

About Magellan Health

Magellan Health, Inc. is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC). Its Pharmacy Management segment consists of products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Its Corporate segment consists primarily of operational support functions. It provides services to health plans and other managed care organizations (MCOs).

Receive News & Ratings for Magellan Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc. and related companies with's FREE daily email newsletter.

Leave a Reply